One of the most important conceptual contributions of this work is demonstrating the power of neuropathology-driven genetic stratification. FTLD-FET has historically been considered a predominantly sporadic condition without a clearly defined genetic architecture^[5]. The identification of GOLGA8A repeat expansions in a substantial proportion of aFTLD-U cases challenges this view and illustrates that strong genetic risk factors may remain hidden when clinically or neuropathologically heterogeneous disease groups are analyzed together^[5]. Importantly, the association appears specific to aFTLD-U, because comparable pathogenic expansions were not identified in neuronal intermediate filament inclusion body disease or basophilic inclusion body disease, the other major FTLD-FET subtypes^[4,5]. These findings reinforce the importance of precise pathological subclassification for identifying disease-specific genomic determinants^[6,7].

Equally notable is the unusual structural architecture of the identified repeat. Repeat expansion disorders are often defined by expansion of a particular sequence motif, but interruptions and changes in motif composition can substantially influence repeat stability, penetrance, and clinical phenotype^[8,9]. The GOLGA8A locus is remarkable for the extent of variation in repeat length, motif length, and sequence composition^[5]. Most importantly, cytosine-thymine (CT) dimer was the only expanded motif observed exclusively on both disease-associated haplotypes A and B. Long CT-dimer-rich alleles were strongly enriched in aFTLD-U and were generally longer than CT-rich alleles observed in unaffected haplotype carriers, whereas CCTT and CCCTCT expansions were also found outside the affected group^[5]. Consistent with this pattern, repeat-based classifiers using either an expansion > 450 bp with > 80% CT content or > 190 CT-dimer units showed stronger associations with aFTLD-U than the individual haplotype-tagging variants^[5]. These observations indicate that pathogenicity is more likely to reflect a combination of repeat length and sequence composition than repeat length alone.

The intronic localization of the expansion raises several mechanistic possibilities, including altered transcription, chromatin regulation, RNA processing, RNA-protein interactions, and repeat-associated translation^[9]. Comparison with other non-coding repeat expansion disorders is informative. In C9orf72-related amyotrophic lateral sclerosis/frontotemporal dementia (ALS/FTD), the expanded G4C2 repeat contributes to disease through convergent mechanisms involving reduced C9orf72 expression, accumulation of repeat-containing RNA, and production of dipeptide repeat proteins through non-canonical translation^[10]. In neuronal intranuclear inclusion disease, a guanine-guanine-cytosine expansion in the 5′ region of NOTCH2NLC can be translated into a toxic polyglycine-containing protein^[11]. No analogous pathogenic RNA species or translated product has yet been demonstrated for the CT-rich GOLGA8A expansion. Its intronic location and dinucleotide composition therefore leave open several possibilities that should currently be considered testable hypotheses rather than established mechanisms^[5,9]. Given the roles of FET-family proteins such as fused in sarcoma and TAF15 in RNA metabolism and ribonucleoprotein organization, it will be particularly important to determine whether CT-rich DNA or RNA alters FET-protein localization, RNA handling, or phase-separated assemblies^[12,13].

The genomic environment of the repeat creates an additional technical and biological challenge. GOLGA8A and its paralog GOLGA8B share approximately 98.9% sequence identity and lie within a region characterized by segmental duplications, copy-number variation, and evidence of recurrent genomic rearrangement^[5,14]. This architecture complicates short-read mapping, transcript assignment, haplotype reconstruction, and gene-expression analysis. The original study itself reported that unique primers could not be designed for one haplotype-tagging variant because the paralogous GOLGA8B sequence was also amplified^[5]. Possible paralog-related regulatory interference, including effects involving the broader GOLGA8 gene cluster, is therefore biologically plausible but remains unproven. Functional studies will require locus- and paralog-specific approaches that can distinguish true effects of the expanded GOLGA8A allele from signals originating from the closely related GOLGA8B locus.

Another important observation is that long CT-rich expansions can be inherited without concurrent clinical disease, indicating incomplete penetrance^[5]. However, asymptomatic status at a single time point should not be interpreted as evidence of lifelong non-penetrance. Age-dependent penetrance is an important alternative explanation, as illustrated by other repeat expansion disorders such as Huntington’s disease, in which the probability and timing of disease manifestation depend on repeat length and age^[15]. This possibility is particularly relevant because the GOLGA8A repeat shows somatic length variation, predominantly within the CT tract^[5]. Additional genetic, epigenetic, environmental, or immune-related modifiers may also influence disease expression, but their contribution has not yet been demonstrated^[5,16]. Longitudinal studies of age-stratified carriers will therefore be essential for distinguishing age-dependent penetrance from persistent resistance to disease and for identifying additional modifiers of clinical expression.

The male predominance observed in the study also requires cautious interpretation. Approximately 71% of aFTLD-U cases carrying the chr15q14 risk haplotypes were male, but a similar male predominance was present in the overall aFTLD-U cohort and among cases without the associated haplotypes^[5]. The sex imbalance should therefore not currently be interpreted as a specific consequence of the GOLGA8A expansion. Instead, it may represent a broader feature of the aFTLD-U pathological subtype or a shared disease-modifying mechanism that operates in both expansion-positive and expansion-negative cases. Hormonal signaling, immune responses, and sex-dependent epigenetic regulation remain plausible modifiers of neurodegenerative disease susceptibility, but future studies will be needed to determine whether these mechanisms influence aFTLD-U generally or specifically modify penetrance among GOLGA8A expansion carriers^[17,18].

Beyond its mechanistic implications, identification of the GOLGA8A repeat has potential relevance for diagnostic stratification. The relationship between CT content, expansion length, and disease status suggests that repeat-based classifiers may ultimately contribute to molecular prediction of aFTLD-U during life^[5]. However, the proposed thresholds were derived from the currently available cohorts and require independent validation, particularly across different populations and in prospectively characterized individuals. Age-dependent penetrance and the presence of long CT-rich expansions in some unaffected carriers must also be incorporated into future risk models^[5]. Accordingly, GOLGA8A repeat profiling should currently be regarded as a promising candidate biomarker rather than an established diagnostic test within precision neurology^[19].

More broadly, this discovery expands the spectrum of repeat-mediated mechanisms implicated in neurodegeneration. Disease-associated tandem repeat expansions are increasingly recognized across Huntington’s disease, C9orf72-associated ALS/FTD, neuronal intranuclear inclusion disease, and ABCA7-associated Alzheimer’s disease risk^[20,21]. The GOLGA8A finding adds a structurally unusual CT-dimer-dominated intronic expansion to this landscape and reinforces the principle that sequence composition can be as biologically relevant as repeat length^[5,8]. At the same time, its marked motif heterogeneity and highly duplicated genomic context distinguish it from better-characterized repeat disorders. Repeat-containing RNAs can influence nuclear and chromatin organization in other settings, but whether this principle applies to GOLGA8A remains to be established experimentally^[22].

The translational implications are intriguing but remain preliminary. Sequence-directed strategies, including antisense oligonucleotides and other RNA-targeting approaches, have created therapeutic opportunities for several repeat-associated disorders^[23]. For GOLGA8A, however, therapeutic development will first require identifying the pathogenic molecular species and determining whether the relevant target is DNA, RNA, or a downstream pathway. The very high homology between GOLGA8A and GOLGA8B creates a major challenge for designing and validating paralog-specific oligonucleotides, whereas the low-complexity CT-rich sequence may introduce additional off-target and specificity constraints. Reliable measurement of target engagement will face the same locus-specificity problem. Furthermore, effective delivery to vulnerable cell populations in the central nervous system remains a general challenge for oligonucleotide therapeutics^[24]. Thus, the current discovery establishes a tractable genetic starting point for therapeutic research rather than an immediately actionable therapeutic target.

Finally, approximately 40% of aFTLD-U cases lacked the chr15q14-associated risk haplotypes, underscoring substantial genetic heterogeneity even within a neuropathologically well-defined disease entity^[5]. These cases may harbor other repeat expansions, structural variants, or distinct pathogenic mechanisms. Long-read sequencing is particularly well suited to resolving tandem repeats and structurally complex genomic regions that remain difficult to characterize with conventional short-read approaches^[25,26]. Extending these analyses to larger neuropathologically defined cohorts may identify additional genetic contributors to aFTLD-U. Equally important will be the development of paralog-specific functional assays, transcriptomic approaches capable of resolving GOLGA8A from GOLGA8B, and longitudinal studies of carriers to establish how repeat architecture, somatic variation, and age jointly influence disease expression.